Together, these mechanisms underscore the importance of the tumour microenvironment in shaping the therapeutic response to GLP-1 RAs and may explain the greater efficacy observed in vivo models compared to isolated in vitro systems. This evidence concerns the gene GLP1R and neoplasm.